What is Ce3?
Founded in 2005, Ce3 operates as a full-service CRO with a distinct focus on early-phase oncology clinical development. The company distinguishes itself through deep technical expertise in high-growth therapeutic areas, specifically immuno-oncology, cell therapies, and gene therapies. By providing comprehensive analytical, regulatory, and investor-focused support, Ce3 serves as an essential bridge for biotech innovators seeking to translate complex scientific research into viable clinical outcomes. Their market position is defined by a commitment to cost-effective, high-quality service delivery that addresses the unique regulatory hurdles inherent in novel modality development.
How much funding has Ce3 raised?
Ce3 has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Ce3
PPP
Public-Private Partnership
What's next for Ce3?
With the successful acquisition of this recent capital, Ce3 is well-positioned to scale its infrastructure to meet the accelerating demand for specialized oncology research services. The strategic deployment of these funds will likely focus on expanding the firm's analytical capabilities and enhancing its regulatory support framework to accommodate the increasing complexity of cell and gene therapy trials. As the biotechnology sector continues to prioritize precision medicine, Ce3's focus on early-phase development provides a robust foundation for sustained growth. The company is expected to leverage this financial momentum to deepen its client relationships and further integrate its service offerings into the global drug development pipeline, ensuring it remains at the forefront of clinical innovation.
See full Ce3 company page
